H E Lebovitz

Summary

Publications

  1. ncbi request reprint Treatment of insulin resistance in diabetes mellitus
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Eur J Pharmacol 490:135-46. 2004
  2. ncbi request reprint Point: visceral adiposity is causally related to insulin resistance
    Harold E Lebovitz
    Division of Endocrinology, Department of Medicine, State University of New York Health Science Center at Brooklyn, USA
    Diabetes Care 28:2322-5. 2005
  3. ncbi request reprint Diabetes: assessing the pipeline
    Harold Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Staten Island, NY 10310 1617, USA
    Atheroscler Suppl 7:43-9. 2006
  4. ncbi request reprint Metabolic consequences of atypical antipsychotic drugs
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, USA
    Psychiatr Q 74:277-90. 2003
  5. ncbi request reprint Insulin resistance--a common link between type 2 diabetes and cardiovascular disease
    Harold E Lebovitz
    Division of Endocrinology and Metabolism Diabetes, State University of New York, Health Science Center, Brooklyn, NY, USA
    Diabetes Obes Metab 8:237-49. 2006
  6. ncbi request reprint Rationale for and role of thiazolidinediones in type 2 diabetes mellitus
    Harold E Lebovitz
    Department of Medicine, Division of Endocrinology, State University of New York Health Science Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Am J Cardiol 90:34G-41G. 2002
  7. ncbi request reprint Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction
    Harold E Lebovitz
    State University of New York, Brooklyn, New York 11203, USA
    Diabetes Care 25:815-21. 2002
  8. ncbi request reprint Differentiating members of the thiazolidinedione class: a focus on safety
    Harold E Lebovitz
    Division of Endocrinology and Metabolism Diabetes, State University of New York, New York, NY, USA
    Diabetes Metab Res Rev 18:S23-9. 2002
  9. ncbi request reprint Effect of the postprandial state on nontraditional risk factors
    H E Lebovitz
    State University of New York Health Sciences Center, Brooklyn, New York 11203, USA
    Am J Cardiol 88:20H-5H. 2001
  10. ncbi request reprint Insulin resistance: definition and consequences
    H E Lebovitz
    State University of New York Health Science Center at Brooklyn, USA
    Exp Clin Endocrinol Diabetes 109:S135-48. 2001

Detail Information

Publications26

  1. ncbi request reprint Treatment of insulin resistance in diabetes mellitus
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Eur J Pharmacol 490:135-46. 2004
    ....
  2. ncbi request reprint Point: visceral adiposity is causally related to insulin resistance
    Harold E Lebovitz
    Division of Endocrinology, Department of Medicine, State University of New York Health Science Center at Brooklyn, USA
    Diabetes Care 28:2322-5. 2005
  3. ncbi request reprint Diabetes: assessing the pipeline
    Harold Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Staten Island, NY 10310 1617, USA
    Atheroscler Suppl 7:43-9. 2006
    ..Such therapies should enable physicians to achieve more for their patients with type 2 diabetes...
  4. ncbi request reprint Metabolic consequences of atypical antipsychotic drugs
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, USA
    Psychiatr Q 74:277-90. 2003
    ..One possible monitoring scheme is outlined and recommendations for treatment are discussed...
  5. ncbi request reprint Insulin resistance--a common link between type 2 diabetes and cardiovascular disease
    Harold E Lebovitz
    Division of Endocrinology and Metabolism Diabetes, State University of New York, Health Science Center, Brooklyn, NY, USA
    Diabetes Obes Metab 8:237-49. 2006
    ..The development of agents with both PPARalpha and PPARgamma activity promises added benefits with amelioration of insulin resistance, delayed progression to and of type 2 diabetes and a reduction of CVD...
  6. ncbi request reprint Rationale for and role of thiazolidinediones in type 2 diabetes mellitus
    Harold E Lebovitz
    Department of Medicine, Division of Endocrinology, State University of New York Health Science Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Am J Cardiol 90:34G-41G. 2002
    ..This article provides an overview of the role of thiazolidinediones in the treatment of type 2 diabetes...
  7. ncbi request reprint Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction
    Harold E Lebovitz
    State University of New York, Brooklyn, New York 11203, USA
    Diabetes Care 25:815-21. 2002
    ....
  8. ncbi request reprint Differentiating members of the thiazolidinedione class: a focus on safety
    Harold E Lebovitz
    Division of Endocrinology and Metabolism Diabetes, State University of New York, New York, NY, USA
    Diabetes Metab Res Rev 18:S23-9. 2002
    ..This article considers safety data obtained from both clinical trials and clinical practice as a means of differentiating among troglitazone, rosiglitazone and pioglitazone...
  9. ncbi request reprint Effect of the postprandial state on nontraditional risk factors
    H E Lebovitz
    State University of New York Health Sciences Center, Brooklyn, New York 11203, USA
    Am J Cardiol 88:20H-5H. 2001
    ....
  10. ncbi request reprint Insulin resistance: definition and consequences
    H E Lebovitz
    State University of New York Health Science Center at Brooklyn, USA
    Exp Clin Endocrinol Diabetes 109:S135-48. 2001
    ..In this context, we need to consider whether insulin resistance should be defined as a disease entity which needs to be diagnosed and treated with specific drugs to improve insulin action...
  11. ncbi request reprint Rosiglitazone monotherapy is effective in patients with type 2 diabetes
    H E Lebovitz
    Department of Medicine, State University of New York, Brooklyn, New York 11203, USA
    J Clin Endocrinol Metab 86:280-8. 2001
    ..In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions...
  12. ncbi request reprint Oral antidiabetic agents: 2004
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Med Clin North Am 88:847-63, ix-x. 2004
    ..The pharmacologic tools currently available are capable of allowing most patients with type 2 diabetes to achieve good metabolic control. Implementation of early combination therapy is essential if glycemic targets are to be met...
  13. ncbi request reprint Insulin resistance and its treatment by thiazolidinediones
    H E Lebovitz
    State University of New York, Health Science Center at Brooklyn, 11203, USA
    Recent Prog Horm Res 56:265-94. 2001
    ....
  14. ncbi request reprint Oral therapies for diabetic hyperglycemia
    H E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA
    Endocrinol Metab Clin North Am 30:909-33. 2001
    ..In choosing combinations of oral antihyperglycemic agents, their effects on the components treatment of type 2 diabetic patients. These classes improve glucose considered, as must the specific effects of the agents on glucose metabolism...
  15. ncbi request reprint Diagnosis, classification, and pathogenesis of diabetes mellitus
    H E Lebovitz
    State University of New York Health Science Center at Brooklyn, USA
    J Clin Psychiatry 62:5-9; discussion 40-1. 2001
    ..A monitoring system should be in place in patients started on treatment with these agents to detect metabolic abnormalities as they are evolving so that adequate and timely treatment can be initiated...
  16. pmc Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm
    H E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA
    Diabet Med 30:687-93. 2013
    ..A preliminary analysis of data from patients who had completed 6 months of treatment indicated that the glycaemic response to the electrical stimulation was inversely related to the baseline fasting plasma triglyceride level...
  17. ncbi request reprint Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men
    M A Banerji
    Department of Medicine, State University of New York Health Science Center, Brooklyn 11203, USA
    J Clin Endocrinol Metab 84:137-44. 1999
    ..Increased visceral fat is related to dyslipidemia and increased frequency of insulin resistance and may account for the increased prevalence of diabetes mellitus and cardiovascular disease in Asian Indians...
  18. ncbi request reprint Type 2 diabetes: an overview
    H E Lebovitz
    SUNY Downstate Medical Center, 450 Clarkson Ave, Box 1205, Brooklyn, NY 11203, USA
    Clin Chem 45:1339-45. 1999
    ..Long-term glycemic control in type 2 diabetes requires progressive, stepwise, combination treatment with oral agents and eventually combination treatment with oral agents and insulin...
  19. doi request reprint Treatment of Patients with Obese Type 2 Diabetes with Tantalus-DIAMOND® Gastric Electrical Stimulation: Normal Triglycerides Predict Durable Effects for at Least 3 Years
    H E Lebovitz
    State University of New York Health Science Center at Brooklyn, Staten Islands, New York, USA
    Horm Metab Res 47:456-62. 2015
    ..It is postulated that this is through a gut-brain interaction that modulates effects on the liver and pancreatic islets...
  20. doi request reprint New treatments of diabetes: the beta-amylin agonists
    H E Lebovitz
    Health Science Center at Brooklyn, Endocrinology and Metabolism Diabetes, State University of New York, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Ann Endocrinol (Paris) 69:147-50. 2008
  21. ncbi request reprint Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
    Peter J Weiden
    Department of Psychiatry, Center for Cognitive Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Neuropsychopharmacology 33:985-94. 2008
    ..These findings demonstrate that switching from risperidone or olanzapine to ziprasidone is associated with sustained, clinically significant improvements in weight and plasma lipids...
  22. ncbi request reprint Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et
    Paul S Jellinger
    Diabetes Care 30:e16-7; author reply e18-20, e21-2. 2007
  23. ncbi request reprint Treating hyperglycemia in type 2 diabetes: new goals and strategies
    Harold E Lebovitz
    Division of Endocrinology and Metabolism Diabetes, State University of New York, SUNY Health Sciences Center, Brooklyn, USA
    Cleve Clin J Med 69:809-20. 2002
    ..This paper discusses the metabolic derangements of type 2 diabetes, the different classes of antihyperglycemic drugs, and strategies for using these drugs rationally...
  24. ncbi request reprint Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies
    Harold E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, USA
    Endocr Pract 12:142-7. 2006
    ..To review new pharmacologic therapies and technologies relevant to the management of diabetes and its complications...
  25. ncbi request reprint ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations
    Harold E Lebovitz
    Endocr Pract 12:6-12. 2006
  26. ncbi request reprint Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004